|
|
Sight Sciences Inc (NASDAQ: SGHT) |
|
|
|
| |
Sight Sciences Inc 's Long Term Debt to Equity
SGHT's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth
Due to net new long-term borrowings of 0.58%, Long Term Debt to Equity fell to 0.51, a new company high.
Within Medical Equipment & Supplies industry in the first quarter 2025, 52 other companies have achieved lower Long Term Debt to Equity than Sight Sciences Inc in the Q1 2025. While Long Term Debt to Equity total ranking has improved so far in the first quarter 2025 to 1263, from total ranking in the fourth quarter 2024 at 1299 .
Explain Long Term Debt to Equity Ratio?
How much Long Term Debts SGHT´s has?
What are SGHT´s Equity?
|
Select the Comparisons :
|
|
Select the Ratio:
|
Long Term Debt to Equity ▼
|
Long Term Debt to Equity ▼
|
| SGHT Long Term Debt to Equity |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Equity Change |
-28.92 % |
-27.19 % |
-25.27 % |
-25.34 % |
-25.39 % |
| Y / Y Long Term Debt Change |
17.47 % |
24.12 % |
1.15 % |
0.49 % |
0.72 % |
| Long Term Debt to Equity MRQ |
0.51 |
0.45 |
0.36 |
0.33 |
0.31 |
| SGHT's Total
Ranking |
# 1263 |
# 1299 |
# 1178 |
# 1103 |
# 1069 |
| Seq. Equity Change |
-11.31 % |
-7.83 % |
-6.57 % |
-6.93 % |
-9.16 % |
| Seq. Long Term Debt Change |
0.58 % |
15.24 % |
1.13 % |
0.22 % |
6.27 % |
| Long Term Debt to Equity first quarter 2025 Company Ranking |
| Within: |
No. |
| Medical Equipment & Supplies Industry |
# 53 |
| Healthcare Sector |
# 143 |
| Overall Market |
# 1263 |
| Long Term Debt to Equity Statistics |
| High |
Average |
Low |
| 0.51 |
0.26 |
0.13 |
| (Mar 31 2025) |
|
(Sep 30 2021) |
Cumulative Sight Sciences Inc 's Long Term Debt to Equity
SGHT's Long Term Debt to Equity for the trailling 12 Months
SGHT Long Term Debt to Equity |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Equity TTM Growth |
-26.57 % |
-25.76 % |
-25.21 % |
-25.57 % |
-26.6 % |
| Y / Y Long Term Debt TTM Growth |
10.61 % |
6.37 % |
-0.61 % |
-0.45 % |
-0.1 % |
| Long Term Debt to Equity TTM |
0.41 |
0.36 |
0.31 |
0.29 |
0.27 |
| Total Ranking TTM |
# 38
| # 31
| # 721
| # 52
| # 50
|
| Seq. Equity TTM Growth |
-8.03 % |
-7.67 % |
-7.01 % |
-7 % |
-7.02 % |
| Seq. Long Term Debt TTM Growth |
4.18 % |
5.74 % |
0.29 % |
0.12 % |
0.18 % |
On the trailing twelve months basis Due to the net new long-term borrowings of 0.58% during the trailing twelve months finishing in the Q1 2025, cumulativeLong Term Debt to Equity improved to 0.41, a new company high. Long Term Debt to Equity is the average cumulative value over the last four quarters.
Among companies in the Medical Equipment & Supplies industry 3, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Sight Sciences Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the Q1 2025, compared to the prior period, from 31 to 38.
Explain Long Term Debt to Equity Ratio?
How much Long Term Debts SGHT´s has?
What are SGHT´s Equity?
| TTM Long Term Debt to Equity Company Ranking |
| Within: |
No. |
| Within the Medical Equipment & Supplies Industry |
# 4 |
| Healthcare Sector |
# 13 |
| Within the Market |
# 38 |
| trailing twelve months Long Term Debt to Equity Statistics |
| High |
Average |
Low |
| 0.41 |
0.24 |
0.15 | | (Mar 31 2025) |
|
(Jun 30 2022) |
| Companies with similar Long Term Debt to Equity in the quarter ending Mar 31 2025, within Medical Equipment & Supplies Industry | Long Term Debt to Equity | Mar 31 2025 MRQ Long Term Debt | Mar 31 2025 MRQ Equity | | Neuronetics Inc | 1.40 | $ 55.341 Millions | $ 39.531 Millions | | Sanara Medtech Inc | 1.22 | $ 44.571 Millions | $ 36.668 Millions | | Insulet Corporation | 1.21 | $ 1,612.300 Millions | $ 1,330.700 Millions | | Cerus Corporation | 1.17 | $ 64.876 Millions | $ 55.492 Millions | | Haemonetics Corporation | 1.12 | $ 921.230 Millions | $ 820.836 Millions | | Artivion Inc | 1.07 | $ 314.611 Millions | $ 294.252 Millions | | Cytosorbents Corporation | 0.98 | $ 14.187 Millions | $ 14.543 Millions | | Conmed Corporation | 0.91 | $ 891.443 Millions | $ 977.636 Millions | | Orchestra Biomed Holdings Inc | 0.85 | $ 14.338 Millions | $ 16.857 Millions | | Dentsply Sirona Inc | 0.79 | $ 1,593.000 Millions | $ 2,010.000 Millions | | Integer Holdings Corporation | 0.77 | $ 1,235.204 Millions | $ 1,606.704 Millions | | Icu Medical Inc | 0.75 | $ 1,488.565 Millions | $ 1,987.689 Millions | | Bausch and Lomb Corp | 0.74 | $ 4,789.000 Millions | $ 6,433.000 Millions | | Integra Lifesciences Holdings Corp | 0.74 | $ 1,128.541 Millions | $ 1,524.139 Millions | | Cvrx inc | 0.71 | $ 49.332 Millions | $ 69.360 Millions | | Masimo Corp | 0.67 | $ 636.000 Millions | $ 946.400 Millions | | Cadre Holdings inc | 0.66 | $ 209.134 Millions | $ 317.562 Millions | | Semler Scientific inc | 0.59 | $ 96.095 Millions | $ 161.683 Millions | | Zimvie Inc | 0.56 | $ 220.618 Millions | $ 395.123 Millions | | Outset Medical Inc | 0.55 | $ 94.115 Millions | $ 169.868 Millions | | Dexcom Inc | 0.55 | $ 1,238.000 Millions | $ 2,266.600 Millions | | Livanova Plc | 0.53 | $ 549.223 Millions | $ 1,034.298 Millions | | Zimmer Biomet Holdings Inc | 0.53 | $ 6,576.300 Millions | $ 12,403.800 Millions | | Enovis Corp | 0.52 | $ 1,367.537 Millions | $ 2,620.218 Millions | | Infusystem Holdings Inc | 0.52 | $ 28.707 Millions | $ 55.148 Millions | | Merit Medical Systems Inc | 0.51 | $ 730.673 Millions | $ 1,428.423 Millions | | Sight Sciences Inc | 0.51 | $ 39.583 Millions | $ 77.628 Millions | | Treace Medical Concepts Inc | 0.51 | $ 53.380 Millions | $ 105.341 Millions | | Henry Schein Inc | 0.50 | $ 1,968.000 Millions | $ 3,954.000 Millions | | Lemaitre Vascular Inc | 0.48 | $ 167.984 Millions | $ 347.572 Millions |
|
